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Introduction 
Excessive morbidity and mortality from influenza 
mostly occurs in older patients with underlying dis- 
ease and can be reduced by immunization (1). In the 
U.K., annual influenza immunization is recom- 
mended for all groups at risk, particularly elderly 
people with chronic respiratory disease (2). Vacci- 
nation rates vary and depend on effective targeting 
by general practitioners and the patient’s willingness 
to accept vaccination when offered (3). Supplies of 
vaccine must also be sufficient to meet demand. 
Previous studies have found serological evidence of 
infection with influenza viruses associated with 
8-13% of chronic airflow limitation (CAL) exacerba- 
tions (4). Other respiratory viruses for which vaccines 
are not currently available may also be important (5). 
The purpose of this study was to establish the influ- 
enza immunization status and reasons for non- 
immunization in middle-aged and elderly patients 
admitted to hospital with exacerbations of CAL, and 
to determine how many of these patients had sero- 
logical evidence of recent infection with respiratory 
viruses. 
Subjects and Methods 
All patients over the age of 50 years admitted to 
our hospital between 1 November 1993 and 31 
March 1994 with an exacerbation of CAL were 
invited to participate in the study. A patient with 
CAL was defined as an individual suffering from any 
chronic respiratory disease requiring maintenance 
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therapy with inhaled or nebulized bronchodilators 
or corticosteroids. An exacerbation was defined as 
subjective deterioration in respiratory symptoms 
necessitating admission to hospital. Patients with 
radiographic evidence of pneumonia or left ventricu- 
lar failure were excluded. Those who agreed to take 
part were asked if the influenza vaccine had been 
administered during Autumn/Winter 1993-1994 and 
the reasons for non-immunization, as stated by the 
patient, were documented. 
Acute and convalescent serum samples were tested 
by complement fixation (CFT) for antibodies to 
influenza A, influenza B, adenovirus, and respiratory 
syncytial virus (RSV). If results from paired sera were 
not available, the reason for this was ascertained. 
Evidence of recent infection was defined as a four- 
fold rise in antibody titre to at least 160 or a single 
antibody titre of greater than 320. Sera from immu- 
nized patients with significant influenza CFT results 
were retested by haemagglutination inhibition assay 
which differentiates antibody responses to vaccine 
from natural infection (6). 
Data were analysed using Epi Info Version 5 
software and significant differences were established 
by Student’s t-test or Yates’ corrected Chi-squared 
test. 
Results 
Two hundred and four patients were approached 
and 195 agreed to take part in the study. Their mean 
age was 70.3 (SD 7.0) years and 102 (52%) were men. 
Influenza immunization status, reasons for non- 
immunizatioin, and serological results are shown in 
Table 1. There were no age or sex differences between 
the immunized and non-immunized patients. Most 
patients who refused immunization did so because of 
adverse effects in themselves or others following 
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Table 1 Influenza immunization status, reasons for non-immunization, and viral serology in 
195 patients with exacerbations of CAL 
Immunized Non-immunized 
Total patients (%) 
Vaccine not offered 
Vaccine offered but refused 
Vaccine contraindicated 
Vaccine accepted but awaited 
Serology 
Evaluable patients 
Age, mean (SD) years 
Influenza A (%) 
RSV (%) 
Adenovirus (%) 
94 (48) 101 (52) 
31 
30 
18 
16 
69 
72.6 (6.6) 69.26;.O) 
1 (1.4)* 13 (20) 
6 @.7Yt 1 (15) 
0 1 (1.5) 
*Yates’ corrected x2= 10.4, RR 0.07 (95% CI 0.01-0.54), P=O+Ol; tnot significant. 
previous influenza vaccination. The most commonly 
cited contraindication was intercurrent illness, and in 
those patients who were awaiting immunization the 
reason was invariably lack of supplies of vaccine. 
Serological results were unavailable in 61 (31%) 
patients: 14 patients had no acute serum sample; two 
patients refused to provide a convalescent serum 
sample; nine patients died; and 36 patients could not 
be contacted after failing to attend for follow-up. 
Vaccination rates in the non-evaluable patients were 
not significantly different (42% vs. 51%) but they 
tended to be older and were more likely to be 
recruited in the last 2 months of the study (30170 vs. 
31/125; OR (odds ratio) 0.41, 95% CIO.21-0.81, 
P=O.OOS). Eleven of the 14 influenza-positive 
patients were recruited in the first 3 months of 
the study. 
Overall, 16.4% of the patients with evaluable serol- 
ogy had evidence of recent viral infection. There were 
significantly more influenza infections in the non- 
immunized patients, and although there were more 
RSV infections in the immunized group this was not 
statistically significant. 
Discussion 
Although only one-half of the patients in this study 
had been immunized against influenza, 158 (81%) 
had been offered immunization by their GPs. The 
48% uptake in our study is similar to other hospital- 
based (7) and community-based (8) studies in which 
immunization rates were 40-50%. The only stated 
contra-indication to influenza immunization is 
known anaphylactic hypersensitivity to egg products 
(2), but general practitioners are clearly unwilling to 
vaccinate patients with intercurrent illness. Uptake is 
also unlikely to improve in patients who initially 
refuse immunization, so strategies designed to 
increase vaccination coverage should concentrate on 
continued targeting of high risk groups and ensuring 
adequate supplies of vaccine. 
This study found evidence of recent infection with 
influenza A in 1% of the evaluable immunized 
patients and 20% of the non-immunized patients. It 
seems likely that the influenza infection rate in this 
study is spuriously high because of the large propor- 
tion of patients with non-evaluable serology who 
were recruited during the last 2 months. The true 
infection rate may be similar to the S-13% found in 
previous studies (4). A hospital-based study such as 
this cannot establish whether influenza infection 
causes exacerbations of CAL. However, this study 
has shown that the viral infections which may lead to 
hospital admission of CAL patients are different in 
immunized and non-immunized individuals. Recent 
community-based studies show that influenza immu- 
nization reduces hospital admissions for elderly 
patients with chronic lung disease (9) and is highly 
cost-effective (10). Annual influenza immunization 
will continue to be recommended for this group of 
patients. 
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